A Randomized Phase II Study to Evaluate the Efficacy of Combined Immunotherapy With Subcutaneous Interleukin-2 and Maxamine in Patients With Metastatic Renal Cell Carcinoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Histamine dihydrochloride; Interleukin-2
- Indications Renal cancer
- Focus Therapeutic Use
- 20 Sep 2013 Biomarkers information updated
- 03 Sep 2005 New trial record.